An association of plasma cyclophilin A with severity of coronary artery disease

Sachin Parhad; Arun Bahulikar; Deepak Phalgune; Ajit Tambolkar; Divya Patel

doi:10.18203/2320-6012.ijrms20251294

Authors

Sachin Parhad Department of Medicine, Poona Hospital and Research Centre, Pune, Maharashtra, India
Arun Bahulikar Department of Medicine, Poona Hospital and Research Centre, Pune, Maharashtra, India
Deepak Phalgune Department of Research, Poona Hospital and Research Centre, Pune, Maharashtra, India
Ajit Tambolkar Department of Medicine, Poona Hospital and Research Centre, Pune, Maharashtra, India
Divya Patel Department of Pathology, Poona Hospital and Research Centre, Pune, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20251294

Keywords:

Association, Coronary artery disease, Cyclophilin A

Abstract

Background: Plasma cyclophilin A (CyPA), an emerging biomarker of cardiovascular disease, is likely to play a crucial role in all stages of atherosclerosis. Very few studies have been conducted on the association of plasma CyPA with coronary artery disease (CAD) in India. The aim of the present study was to determine an association between plasma CyPA levels and CAD severity.

Methods: The present cross-sectional observational study was conducted on 100 patients aged ≥18 years who presented with symptoms suggestive of CAD. The presence or absence of cardiovascular risk factors such as gender, hypertension, diabetes mellitus, dyslipidaemia, family H/O CAD, smoking, etc. were noted. Coronary angiography was performed on each patient. Quantitative estimation of plasma CypA levels and high-sensitivity C-reactive protein (hs-CRP) was done.

Results: The mean serum CypA (66.6 Vs 44.9 ng/ml) and hs-CRP (29.8 Vs 21.4 mg/l) were significantly higher in patients with obstructive CAD as compared to non-obstructive CAD. There was a statistically significant positive correlation (r=0.251) between CypA levels and hs-CRP (p value=0.012). The mean low-density lipoprotein cholesterol (181 Vs 160.8 mg/dL) and mean triglycerides (179 Vs 168 mg/dl) were significantly higher in patients with obstructive CAD as compared to non-obstructive CAD. There was no statistically significant difference between the type of CAD and mean total cholesterol and high-density lipoprotein cholesterol.

Conclusions: CypA levels were increased in obstructive CAD patients. High CypA serum levels could be a novel biomarker in CAD patients associated with severe CAD.

Metrics

Metrics Loading ...

References

WHO. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva, World Health Organization. 2002.

Reddy KS. Cardiovascular disease in non-Western countries. N Engl J Med. 2004;350:2438-40. DOI: https://doi.org/10.1056/NEJMp048024

Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res. 1996;33:181-94. DOI: https://doi.org/10.1159/000159147

Tiwari RP, Jain A, Khan Z. Cardiac troponins I and T: molecular markers for early diagnosis, prognosis and accurate triaging of patients with acute myocardial infarction. Mol Diagn Ther. 2012;16:371-81. DOI: https://doi.org/10.1007/s40291-012-0011-6

Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352:1685-95. DOI: https://doi.org/10.1056/NEJMra043430

Dzau VJ, Antman EM, Black HR. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-70. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.655688

Jin ZG, Melaragno MG, Liao DF. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res. 2000;87:789-96. DOI: https://doi.org/10.1161/01.RES.87.9.789

Liao DF, Jin ZG, Baas AS. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem. 2000;275:189-96. DOI: https://doi.org/10.1074/jbc.275.1.189

Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal. 2010;12:675-82. DOI: https://doi.org/10.1089/ars.2009.2875

Satoh K, Shimokawa H, Berk BC. Cyclophilin A: promising new target in cardiovascular therapy. Circ J. 2010;74:2249-56. DOI: https://doi.org/10.1253/circj.CJ-10-0904

Thomas M, Gavrila D, McCormick ML. Deletion of p47phox attenuates angiotensin II–induced abdominal aortic aneurysm formation in apolipoprotein E–deficient mice. Circulation. 2006;114:404-13. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.607168

Libby P, Okamoto Y, Rocha VZ. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213-20. DOI: https://doi.org/10.1253/circj.CJ-09-0706

Tian H, Yu D, Hu Y. Angiotensin II upregulates cyclophilin A by enhancing ROS production in rat cardiomyocytes. Mol Med Rep. 2018;18:4349-55. DOI: https://doi.org/10.3892/mmr.2018.9448

Arnett DK, Blumenthal RS, Albert MA. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140:596-646. DOI: https://doi.org/10.1161/CIR.0000000000000725

McEvoy JW, Daya N, Rahman F. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA. 2020;323:329-38. DOI: https://doi.org/10.1001/jama.2019.21402

Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231-7. DOI: https://doi.org/10.1242/dmm.001180

Kuzuya T, Nakagawa S, Satoh J. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65-85. DOI: https://doi.org/10.1016/S0168-8227(01)00365-5

Maddox TM, Stanislawski MA, Grunwald GK. Nonobstructive coronary disease and risk of myocardial infraction. JAMA. 2014;312:1754-63. DOI: https://doi.org/10.1001/jama.2014.14681

Alfonso A, Bayón J, Gegunde S. High Serum Cyclophilin C levels as a risk factor marker for coronary artery disease. Sci Rep. 2019;9:10576. DOI: https://doi.org/10.1038/s41598-019-46988-x

Manaswini N, Sreedevi N, Thummala S. Association of Serum Cyclophilin A Levels with Severity of Coronary Artery Disease. J Lab Physicians. 2022;14:253-9. DOI: https://doi.org/10.1055/s-0042-1742418

Yan J, Zang X, Chen R. The clinical implications of increased cyclophilin A levels in patients with acute coronary syndromes. Clin Chim Acta. 2012;413:691-5. DOI: https://doi.org/10.1016/j.cca.2011.12.009

Ebrahim HF, Abdel Hamid FF. Cyclophilin A and matrix metalloproteinase-9: Their relationship, association with and diagnostic relevance in stable coronary artery disease. Vascular. 2020;28:212-21. DOI: https://doi.org/10.1177/1708538119879589

Bayon J, Alfonso A, Gegunde S. Cyclophilins in Ischemic Heart Disease: Differences Between Acute and Chronic Coronary Artery Disease Patients. Cardiol Res. 2020;11:319-27. DOI: https://doi.org/10.14740/cr1120

Satoh K, Fukumoto Y, Sugimura K. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J. 2013;77:447-55. DOI: https://doi.org/10.1253/circj.CJ-12-0805